Tharimmune (THAR) to Merge With Intract Pharma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. ARTV
8. AAPL
9. SSD
10. BA

Go back to Tharimmune (THAR) to Merge With Intract Pharma

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

September 30, 2024 7:21 AM EDT

- Business combination to form a best-in-class, transformative oral biologics company
- Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth
- Merger anticipated to close in 1Q25

BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, and Intract Pharma Ltd. ("Intract"), a biopharmaceutical company developing disruptive delivery solutions for oral... More